Immunological Approaches in the Treatment of Metastasized Breast Cancer

被引:7
作者
Mueller, Volkmar [1 ]
Witzel, Isabell [1 ]
Stickeler, Elmar [2 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Gynecol, Hamburg, Germany
[2] Univ Freiburg, Dept Obstet & Gynecol, D-7800 Freiburg, Germany
关键词
Breast cancer; Metastasis; Antibody; Therapy; GROWTH-FACTOR RECEPTOR; MULTICENTER PHASE-II; DEPENDENT CELLULAR CYTOTOXICITY; MONOCLONAL-ANTIBODY; 1ST-LINE TREATMENT; OPEN-LABEL; TRASTUZUMAB; EFFICACY; HER2; SAFETY;
D O I
10.1159/000262454
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A better understanding of tumor biology has led to the development of a number of antibody-based targeted therapies in breast cancer. Several of these newer agents, such as trastuzumab and bevacizumab have demonstrated clinical activity and have improved the treatment of patients with metastatic breast cancer (MBC). Trastuzumab is a monoclonal antibody that binds to the extracellular domain of the HER2 receptor. The addition of trastuzumab to chemotherapy and also to endocrine therapy has enhanced efficacy of treatment. New antibody-based strategies directed against HER2 are under development. These new approaches include pertuzumab, an antibody with a different binding epitope that inhibits dimerization of HER2 with other members of the HER receptor family and TDM1, a trastuzumab-based antibody chemotherapeutic conjugate. Another approach to the treatment of solid tumors is inhibition of angiogenesis. The anti-VEGF antibody bevacizumab has been approved for treatment of MBC. Although the mechanism of action is still under investigation, bevacizumab is tested in other clinical settings such as adjuvant therapy, maintenance therapy, and in combination with both chemotherapy and other targeted agents. In this review, we will summarize the most important studies on trastuzumab and bevacizumab, and describe new antibodies currently under clinical development.
引用
收藏
页码:358 / 366
页数:8
相关论文
共 50 条
[41]   A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric Cancer [J].
Jorgensen, Jan Trost ;
Winther, Henrik ;
Askaa, Jon ;
Andresen, Lena ;
Olsen, Dana ;
Mollerup, Jens .
FRONTIERS IN ONCOLOGY, 2021, 11
[42]   Reduced in vivo lung metastasis of a breast cancer cell line after treatment with Herceptin mAb conjugated to chemotherapeutic drugs [J].
Garcia, A. Galan ;
Nedev, H. ;
Bijian, K. ;
Su, J. ;
Alaoui-Jamali, M. A. ;
Saragovi, H. U. .
ONCOGENE, 2013, 32 (20) :2527-2533
[43]   New therapeutic approaches in breast cancer [J].
Davies, Eleri ;
Hiscox, Stephen .
MATURITAS, 2011, 68 (02) :121-128
[44]   Locoregional treatment in oligometastatic breast cancer: A case report and review of treatment approaches in the era of cyclin inhibitors [J].
Koh, Samantha Shui Yuan ;
Pereira, Adriana Dantas Amaro ;
de Paula, Bruno Henrique Rala ;
Millen, Eduardo Camargo ;
McAdam, Karen .
CURRENT PROBLEMS IN CANCER: CASE REPORTS, 2022, 5
[45]   Immunotherapeutic approaches for the treatment of breast cancer [J].
Knutson, KL ;
Schiffman, K ;
Rinn, K ;
Disis, ML .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 1999, 4 (04) :353-365
[46]   Immunotherapeutic Approaches for the Treatment of Breast Cancer [J].
Keith L. Knutson ;
Kathy Schiffman ;
Kristine Rinn ;
Mary L. Disis .
Journal of Mammary Gland Biology and Neoplasia, 1999, 4 :353-365
[47]   Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+breast cancer [J].
Gagliato, Debora de Melo ;
Fontes Jardim, Denis Leonardo ;
Pereira Marchesi, Mario Sergio ;
Hortobagyi, Gabriel N. .
ONCOTARGET, 2016, 7 (39) :64431-64446
[48]   Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment [J].
Liu, Shuying ;
Xie, Shelly M. ;
Liu, Wenbin ;
Gagea, Mihai ;
Hanker, Ariella B. ;
Nguyen, Nguyen ;
Raghavendra, Akshara Singareeka ;
Yang-Kolodji, Gloria ;
Chu, Fuliang ;
Neelapu, Sattva S. ;
Marchese, Adriano ;
Hanash, Samir ;
Zimmermann, Johann ;
Arteaga, Carlos L. ;
Tripathy, Debasish .
BREAST CANCER RESEARCH, 2023, 25 (01)
[49]   Possible available treatment option for early stage, small, node-negative, and HER2-overexpressing breast cancer [J].
Araki, Kazuhiro ;
Saji, Shigehira ;
Gallas, Michelle ;
Pegram, Mark ;
Sasaki, Yasutsuna .
BREAST CANCER, 2012, 19 (02) :95-103
[50]   Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer [J].
Ishihara, Mikiya ;
Mukai, Hirofumi ;
Nagai, Shunji ;
Mukohara, Toru .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (05) :431-435